Rehovot, Israel

Racheli Gueta

This inventor holds 1 USPTO granted patent and 6 published patent applications and 1 EPO patent. Top assignee: Collplant Ltd.. Active years: 2019.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Racheli Gueta: Innovator in Tissue Regeneration

Introduction

Racheli Gueta is a prominent inventor based in Rehovot, Israel. She has made significant contributions to the field of tissue regeneration through her innovative research and development. Her work focuses on the use of collagen and platelet-rich plasma (PRP) to enhance healing processes.

Latest Patents

Racheli Gueta holds a patent for her invention titled "Compositions comprising collagen and PRP for tissue regeneration." This patent describes a composition of matter that includes crosslinked collagen, platelet-rich plasma, and an inorganic salt. The patent also outlines methods for generating this composition and its various uses in medical applications.

Career Highlights

Racheli is associated with Collplant Ltd., a company dedicated to advancing regenerative medicine. Her role at the company allows her to apply her innovative ideas in practical settings, contributing to the development of new therapies for tissue repair and regeneration.

Collaborations

Racheli has collaborated with notable colleagues, including Oded Shoseyov and Frida Grynspan Gotlieb. These partnerships have fostered a collaborative environment that enhances the research and development of innovative solutions in the field.

Conclusion

Racheli Gueta's work exemplifies the intersection of innovation and practical application in the medical field. Her contributions to tissue regeneration through her patented compositions highlight her role as a leading inventor in this important area of research.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…